Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”
Circulation · 04.08.2026 · 154 (5)
DOI: 10.1161/circulationaha.126.080024 ↗Kurz gefasst
Leserbrief in der Zeitschrift Circulation, erschienen am 04.08.2026. Verfasst von Congxiao Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Hujun Wang
Zitieren
APA
Wang, C., & Wang, H. (2026). Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation, 154(5). https://doi.org/10.1161/circulationaha.126.080024
Vancouver
Wang C, Wang H. Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation. 2026;154(5). doi:10.1161/circulationaha.126.080024
BibTeX
@article{Wang2026,
author = {Wang, Congxiao and Wang, Hujun},
title = {Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”},
journal = {Circulation},
year = {2026},
volume = {154},
number = {5},
doi = {10.1161/circulationaha.126.080024}
}
EUVIMED